Gerald Batist

20.2k total citations · 6 hit papers
329 papers, 13.2k citations indexed

About

Gerald Batist is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gerald Batist has authored 329 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Oncology, 130 papers in Molecular Biology and 54 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gerald Batist's work include Cancer Treatment and Pharmacology (45 papers), Glutathione Transferases and Polymorphisms (39 papers) and Colorectal Cancer Treatments and Studies (39 papers). Gerald Batist is often cited by papers focused on Cancer Treatment and Pharmacology (45 papers), Glutathione Transferases and Polymorphisms (39 papers) and Colorectal Cancer Treatments and Studies (39 papers). Gerald Batist collaborates with scholars based in Canada, United States and France. Gerald Batist's co-authors include Charles E. Myers, Kenneth H. Cowan, Birandra K. Sinha, Aspandiar G. Katki, Moulay A. Alaoui‐Jamali, Anil Tulpule, Weimin Miao, Mustapha Kandouz, P. James Scrivens and George D. Carystinos and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Biological Chemistry.

In The Last Decade

Gerald Batist

312 papers receiving 12.8k citations

Hit Papers

Comparison of Oral Capeci... 1985 2026 1998 2012 2001 2016 1986 2013 2001 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
    2001 882 citations Gerald Batist et al. Journal of Clinical Oncology profile →
  2. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions
    2016 877 citations Gerald Batist et al. profile →
  3. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.
    1986 724 citations Gerald Batist et al. Journal of Biological Chemistry profile →
  4. Use of Statins and the Risk of Death in Patients With Prostate Cancer
    2013 512 citations Oriana Hoi Yun Yu, María Eberg et al. Journal of Clinical Oncology profile →
  5. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
    2001 507 citations Gerald Batist et al. Journal of Clinical Oncology profile →
  6. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion
    1985 493 citations Gerald Batist et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gerald Batist 5.6k 4.8k 1.7k 1.7k 1.4k 329 13.2k
Joan L. Kramer 4.8k 0.9× 6.4k 1.3× 3.3k 2.0× 3.3k 2.0× 1.1k 0.8× 14 15.4k
Dong Wang 8.5k 1.5× 3.9k 0.8× 1.5k 0.9× 3.0k 1.8× 986 0.7× 548 15.9k
Merrill J. Egorin 5.9k 1.1× 5.5k 1.1× 2.2k 1.3× 1.0k 0.6× 529 0.4× 380 14.2k
Rebecca L. Siegel 3.4k 0.6× 4.4k 0.9× 2.4k 1.4× 2.1k 1.2× 768 0.6× 7 10.5k
Frank M. Torti 7.5k 1.3× 3.1k 0.6× 3.6k 2.1× 2.5k 1.5× 1.0k 0.7× 240 21.9k
Keon Wook Kang 4.0k 0.7× 2.0k 0.4× 2.1k 1.2× 1.5k 0.9× 1.4k 1.0× 396 13.0k
Ron H.J. Mathijssen 5.1k 0.9× 7.2k 1.5× 3.5k 2.1× 1.7k 1.0× 463 0.3× 453 14.3k
Olaf van Tellingen 5.3k 1.0× 10.0k 2.1× 1.4k 0.8× 1.1k 0.7× 995 0.7× 238 16.1k
Angelo Vacca 9.9k 1.8× 6.7k 1.4× 1.3k 0.8× 2.8k 1.7× 644 0.5× 494 22.9k
Maurizio D’Incalci 8.4k 1.5× 6.5k 1.4× 3.2k 1.9× 3.2k 1.9× 463 0.3× 531 17.4k

Countries citing papers authored by Gerald Batist

Since Specialization
Citations

This map shows the geographic impact of Gerald Batist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Batist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Batist more than expected).

Fields of papers citing papers by Gerald Batist

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Batist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Batist. The network helps show where Gerald Batist may publish in the future.

Co-authorship network of co-authors of Gerald Batist

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Batist. A scholar is included among the top collaborators of Gerald Batist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Batist. Gerald Batist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dankner, Matthew, Mark Sorin, Jamie Magrill, et al.. (2025). Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis. Current Oncology. 32(11). 624–624.
2.
MacDonald, Karen V., Gerald Batist, Winson Y. Cheung, et al.. (2025). Patient Preferences for Metastatic Colorectal Cancer Treatment: A Multi-method Approach Using Discrete Choice Experiments and Best–Worst Scaling. Patient. 18(6). 747–761.
3.
4.
Dankner, Matthew, David W. Cescon, Anna Spreafico, et al.. (2024). The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers. Cancers. 16(2). 445–445. 7 indexed citations
5.
Stewart, David J., Sandeep Sehdev, Vishal Navani, et al.. (2024). New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices. Current Oncology. 31(5). 2453–2480. 5 indexed citations
6.
Sobsey, Constance A., Robert Popp, René P. Zahedi, et al.. (2024). mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA -Altered Tumors. Cancer Research Communications. 4(8). 2058–2074. 2 indexed citations
7.
Gambaro, Karen, Maud Marques, Cyrla Hoffert, et al.. (2023). A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy. International Journal of Molecular Sciences. 25(1). 43–43.
8.
Gambaro, Karen, Arif Awan, Mahmoud Abdelsalam, et al.. (2023). Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada. Journal of Pharmacy & Pharmaceutical Sciences. 26. 12078–12078.
9.
Stewart, David J., et al.. (2022). Treatment Access, Health Economics, and the Wave of a Magic Wand. Current Oncology. 29(2). 1176–1189. 3 indexed citations
10.
Liu, Xiaoyang, Farhad Maleki, Nikesh Muthukrishnan, et al.. (2021). Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models. Cancers. 13(15). 3723–3723. 5 indexed citations
11.
Batist, Gerald, et al.. (2020). Orally Administered Multiple Dose Saltikva (Salmonella-IL2) in Conjunction with Folfirinox in a Patient with Stage IV Pancreatic Cancer: A Case Report. 2020(3). 1–4. 3 indexed citations
12.
Marques, Maud, Lise Tremblay, Nicole Bouchard, et al.. (2019). Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. Molecular Cancer Therapeutics. 18(9). 1628–1636. 20 indexed citations
13.
Aboulkassim, Tahar, et al.. (2016). Nrf2 Transcription Factor Can Directly Regulate mTOR. Journal of Biological Chemistry. 291(49). 25476–25488. 77 indexed citations
14.
Yu, Oriana Hoi Yun, María Eberg, Serge Benayoun, et al.. (2013). Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology. 32(1). 5–11. 512 indexed citations breakdown →
15.
Batist, Gerald, Karen A. Gelmon, Kim N., et al.. (2009). Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(2). 692–700. 166 indexed citations
16.
Theodoulou, Maria, Gerald Batist, Susana M. Campos, et al.. (2009). Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer. 9(2). 101–107. 11 indexed citations
17.
Batist, Gerald, John Sarantopoulos, Kamalesh K. Sankhala, et al.. (2007). A phase I and pharmacokinetic (PK) study of vinorelbine liposomes injection in patients with advanced solid tumors, non-Hodgkin’s lymphoma, and Hodgkin’s disease. Molecular Cancer Therapeutics. 6. 1 indexed citations
18.
Batist, Gerald. (2005). Surrogate Endpoints in Colorectal Cancer. Current Oncology. 12(4). 1 indexed citations
19.
Seiden, Michael V., Kenneth D. Swenerton, Ursula A. Matulonis, et al.. (2002). A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy. Gynecologic Oncology. 86(3). 302–310. 80 indexed citations
20.
Alpert, Laurence I., et al.. (2001). Regulation of the gap junction connexin 43 gene by androgens in the prostate. Journal of Molecular Endocrinology. 26(1). 1–10. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan L. Kramer Breakdown of academic impact, for papers by Dong Wang Breakdown of academic impact, for papers by Merrill J. Egorin Breakdown of academic impact, for papers by Rebecca L. Siegel Breakdown of academic impact, for papers by Frank M. Torti Breakdown of academic impact, for papers by Keon Wook Kang Breakdown of academic impact, for papers by Ron H.J. Mathijssen Breakdown of academic impact, for papers by Olaf van Tellingen Breakdown of academic impact, for papers by Angelo Vacca Breakdown of academic impact, for papers by Maurizio D’Incalci
Rankless by CCL
2026